Literature DB >> 9808182

Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells.

C A Chambers1, T J Sullivan, T Truong, J P Allison.   

Abstract

Negative as well as positive co-stimulation appears to play an important role in controlling T cell activation. CTLA-4 has been proposed to negatively regulate T cell responses. CTLA-4-deficient mice develop a lymphoproliferative disorder, initiated by the activation and expansion of CD4+ T cells. To assess the function of CTLA-4 on CD8+ T cells, CTLA-4(-/-) animals were crossed to an MHC class I-restricted 2C TCR transgenic mouse line. We demonstrate that although the primary T cell responses were similar, the CTLA-4-deficient 2C TCR+ CD8+ T cells displayed a greater proliferative response upon secondary stimulation than the 2C TCR+ CD8+ T cells from CTLA-4 wild-type mice. These results suggest that CTLA-4 regulates antigen-specific memory CD8+ T cell responses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808182     DOI: 10.1002/(SICI)1521-4141(199810)28:10<3137::AID-IMMU3137>3.0.CO;2-X

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  39 in total

Review 1.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

Review 2.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

3.  Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance.

Authors:  Virginia A Pedicord; Welby Montalvo; Ingrid M Leiner; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

Review 4.  Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.

Authors:  Margaret K Callahan; Jedd D Wolchok; James P Allison
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

5.  Cellular uptake followed by class I MHC presentation of some exogenous peptides contributes to T cell stimulatory capacity.

Authors:  Susan E Brophy; Lindsay L Jones; Phillip D Holler; David M Kranz
Journal:  Mol Immunol       Date:  2006-12-12       Impact factor: 4.407

6.  CD8(+) T cells resistant to costimulatory blockade are controlled by an antagonist interleukin-15/Fc protein.

Authors:  Sylvie Ferrari-Lacraz; Xin Xiao Zheng; Alberto Sanchez Fueyo; Wlodzimierz Maslinski; Thomas Moll; Terry B Strom
Journal:  Transplantation       Date:  2006-12-15       Impact factor: 4.939

7.  Mice deficient in perforin, CD4+ T cells, or CD28-mediated signaling maintain the typical immunodominance hierarchies of CD8+ T-cell responses to influenza virus.

Authors:  Weisan Chen; Jack R Bennink; Phillip A Morton; Jonathan W Yewdell
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity.

Authors:  William Stohl; Noam Jacob; William J Quinn; Michael P Cancro; Huaxin Gao; Chaim Putterman; Xiaoni Gao; Luminita Pricop; Michael N Koss
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

9.  Tpl2 and ERK transduce antiproliferative T cell receptor signals and inhibit transformation of chronically stimulated T cells.

Authors:  Christos Tsatsanis; Katerina Vaporidi; Vassiliki Zacharioudaki; Ariadne Androulidaki; Yuri Sykulev; Andrew N Margioris; Philip N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

10.  Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.

Authors:  Karl S Peggs; Sergio A Quezada; Cynthia A Chambers; Alan J Korman; James P Allison
Journal:  J Exp Med       Date:  2009-07-06       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.